P53 N-terminal Phosphorylation: a Defining Layer of Complex Regulation

Overview

Journal Carcinogenesis

Specialty Oncology

Date 2012 Apr 17

PMID 22505655

Citations 56

Authors

Lisa M Miller Jenkins

Stewart R Durell

Sharlyn J Mazur

Ettore Appella

Affiliations

Soon will be listed here.

Abstract

The p53 tumor suppressor is a critical component of the cellular response to stress. As it can inhibit cell growth, p53 is mutated or functionally inactivated in most tumors. A multitude of protein-protein interactions with transcriptional cofactors are central to p53-dependent responses. In its activated state, p53 is extensively modified in both the N- and C-terminal regions of the protein. These modifications, especially phosphorylation of serine and threonine residues in the N-terminal transactivation domain, affect p53 stability and activity by modulating the affinity of protein-protein interactions. Here, we review recent findings from in vitro and in vivo studies on the role of p53 N-terminal phosphorylation. These modifications can either positively or negatively affect p53 and add a second layer of complex regulation to the divergent interactions of the p53 transactivation domain.

Citing Articles

PBLD enhances antiviral innate immunity by promoting the p53-USP4-MAVS signaling axis.

Chu F, Hou P, Zhu H, Gao Y, Wang X, He W Proc Natl Acad Sci U S A. 2024; 121(49):e2401174121.

PMID: 39589880 PMC: 11626120. DOI: 10.1073/pnas.2401174121.

TP53 mutations in cancer: Molecular features and therapeutic opportunities (Review).

Tornesello M Int J Mol Med. 2024; 55(1).

PMID: 39450536 PMC: 11554381. DOI: 10.3892/ijmm.2024.5448.

Jun Dimerization Protein 2 (JDP2) Increases p53 Transactivation by Decreasing MDM2.

Price K, Yang W, Cardoso L, Wang C, Yang R, Yang W Cancers (Basel). 2024; 16(5).

PMID: 38473360 PMC: 10930919. DOI: 10.3390/cancers16051000.

Exploring the Role of Globular Domain Locations on an Intrinsically Disordered Region of p53: A Molecular Dynamics Investigation.

Bakker M, Sorensen H, Skepo M J Chem Theory Comput. 2024; 20(3):1423-1433.

PMID: 38230670 PMC: 10867847. DOI: 10.1021/acs.jctc.3c00971.

Targeting 7KCh-Induced Cell Death Response Mediated by p38, P2X7 and GSDME in Retinal Pigment Epithelium Cells with Sterculic Acid.

Pariente A, Pelaez R, Ochoa R, Perez-Sala A, Villanueva-Martinez A, Bobadilla M Pharmaceutics. 2023; 15(11).

PMID: 38004569 PMC: 10675123. DOI: 10.3390/pharmaceutics15112590.

References

Chan W, Mak M, Kan Fung T, Lau A, Siu W, Poon R . Ubiquitination of p53 at multiple sites in the DNA-binding domain. Mol Cancer Res. 2006; 4(1):15-25. DOI: 10.1158/1541-7786.MCR-05-0097. View

Kumamoto K, Spillare E, Fujita K, Horikawa I, Yamashita T, Appella E . Nutlin-3a activates p53 to both down-regulate inhibitor of growth 2 and up-regulate mir-34a, mir-34b, and mir-34c expression, and induce senescence. Cancer Res. 2008; 68(9):3193-203. PMC: 2440635. DOI: 10.1158/0008-5472.CAN-07-2780. View

Livengood J, Scoggin K, Van Orden K, McBryant S, Edayathumangalam R, Laybourn P . p53 Transcriptional activity is mediated through the SRC1-interacting domain of CBP/p300. J Biol Chem. 2002; 277(11):9054-61. DOI: 10.1074/jbc.M108870200. View

Polley S, Guha S, Roy N, Kar S, Sakaguchi K, Chuman Y . Differential recognition of phosphorylated transactivation domains of p53 by different p300 domains. J Mol Biol. 2007; 376(1):8-12. DOI: 10.1016/j.jmb.2007.11.082. View

Avantaggiati M, Ogryzko V, Gardner K, Giordano A, Levine A, Kelly K . Recruitment of p300/CBP in p53-dependent signal pathways. Cell. 1997; 89(7):1175-84. DOI: 10.1016/s0092-8674(00)80304-9. View

Johnson T, Hammond E, Giaccia A, Attardi L . The p53QS transactivation-deficient mutant shows stress-specific apoptotic activity and induces embryonic lethality. Nat Genet. 2005; 37(2):145-52. DOI: 10.1038/ng1498. View

Dai C, Gu W . p53 post-translational modification: deregulated in tumorigenesis. Trends Mol Med. 2010; 16(11):528-36. PMC: 2978905. DOI: 10.1016/j.molmed.2010.09.002. View

Brady C, Jiang D, Mello S, Johnson T, Jarvis L, Kozak M . Distinct p53 transcriptional programs dictate acute DNA-damage responses and tumor suppression. Cell. 2011; 145(4):571-83. PMC: 3259909. DOI: 10.1016/j.cell.2011.03.035. View

Melis J, Hoogervorst E, van Oostrom C, Zwart E, Breit T, Pennings J . Genotoxic exposure: novel cause of selection for a functional ΔN-p53 isoform. Oncogene. 2010; 30(15):1764-72. DOI: 10.1038/onc.2010.552. View

10.

Ozeki C, Sawai Y, Shibata T, Kohno T, Okamoto K, Yokota J . Cancer susceptibility polymorphism of p53 at codon 72 affects phosphorylation and degradation of p53 protein. J Biol Chem. 2011; 286(20):18251-60. PMC: 3093897. DOI: 10.1074/jbc.M110.208587. View

11.

Oldfield C, Meng J, Yang J, Yang M, Uversky V, Dunker A . Flexible nets: disorder and induced fit in the associations of p53 and 14-3-3 with their partners. BMC Genomics. 2008; 9 Suppl 1:S1. PMC: 2386051. DOI: 10.1186/1471-2164-9-S1-S1. View

12.

Popowicz G, Czarna A, Holak T . Structure of the human Mdmx protein bound to the p53 tumor suppressor transactivation domain. Cell Cycle. 2008; 7(15):2441-3. DOI: 10.4161/cc.6365. View

13.

Scolnick D, Chehab N, Stavridi E, LIEN M, Caruso L, Moran E . CREB-binding protein and p300/CBP-associated factor are transcriptional coactivators of the p53 tumor suppressor protein. Cancer Res. 1997; 57(17):3693-6. View

14.

Donehower L, Harvey M, Slagle B, McArthur M, Montgomery Jr C, Butel J . Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature. 1992; 356(6366):215-21. DOI: 10.1038/356215a0. View

15.

Rodriguez M, Desterro J, Lain S, Lane D, Hay R . Multiple C-terminal lysine residues target p53 for ubiquitin-proteasome-mediated degradation. Mol Cell Biol. 2000; 20(22):8458-67. PMC: 102152. DOI: 10.1128/MCB.20.22.8458-8467.2000. View

16.

Yakovlev V, Bayden A, Graves P, Kellogg G, Mikkelsen R . Nitration of the tumor suppressor protein p53 at tyrosine 327 promotes p53 oligomerization and activation. Biochemistry. 2010; 49(25):5331-9. PMC: 2892261. DOI: 10.1021/bi100564w. View

17.

Johnson T, Attardi L . p53QS: an old mutant teaches us new tricks. Cell Cycle. 2005; 4(6):731-4. DOI: 10.4161/cc.4.6.1696. View

18.

Debnath S, Chatterjee S, Arif M, Kundu T, Roy S . Peptide-protein interactions suggest that acetylation of lysines 381 and 382 of p53 is important for positive coactivator 4-p53 interaction. J Biol Chem. 2011; 286(28):25076-87. PMC: 3137081. DOI: 10.1074/jbc.M110.205328. View

19.

Barlev N, Liu L, Chehab N, Mansfield K, Harris K, Halazonetis T . Acetylation of p53 activates transcription through recruitment of coactivators/histone acetyltransferases. Mol Cell. 2002; 8(6):1243-54. DOI: 10.1016/s1097-2765(01)00414-2. View

20.

Shouse G, Cai X, Liu X . Serine 15 phosphorylation of p53 directs its interaction with B56gamma and the tumor suppressor activity of B56gamma-specific protein phosphatase 2A. Mol Cell Biol. 2007; 28(1):448-56. PMC: 2223295. DOI: 10.1128/MCB.00983-07. View